Show simple item record

dc.contributor.authorMitchell, Jane A.
dc.contributor.authorAhmetaj-Shala, Blerina
dc.contributor.authorKirkby, Nick
dc.contributor.authorWright, William R.
dc.contributor.authorMacKenzie, Louise Susan
dc.contributor.authorReed, Dan
dc.contributor.authorMohamed, Nura
dc.date.accessioned2015-01-06T14:32:35Z
dc.date.available2015-01-06T14:32:35Z
dc.date.issued2014-12-31
dc.identifier.citationMitchell , J A , Ahmetaj-Shala , B , Kirkby , N , Wright , W R , MacKenzie , L S , Reed , D & Mohamed , N 2014 , ' Role of prostacyclin in pulmonary hypertension ' , Global Cardiology Science and Practice , vol. 2014 , no. 4 , 53 . https://doi.org/10.5339/gcsp.2014.53
dc.identifier.issn2305-7823
dc.identifier.otherPURE: 7929880
dc.identifier.otherPURE UUID: 543f506a-00bc-4494-a3c9-bd1e3ed4ce1f
dc.identifier.urihttp://hdl.handle.net/2299/15089
dc.descriptionDate of Acceptance: 11/12/2014 This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY-4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.
dc.description.abstractProstacyclin is a powerful cardioprotective hormone released by the endothelium of all blood vessels. Prostacyclin exists in equilibrium with other vasoactive hormones and a disturbance in the balance of these factors leads to cardiovascular disease including pulmonary arterial hypertension. Since it’s discovery in the 1980s concerted efforts have been made to make the best therapeutic utility of prostacyclin, particularly in the treatment of pulmonary arterial hypertension. This has centred on working out the detailed pharmacology of prostacyclin and then synthesising new molecules based on its structure that are more stable or more easily tolerated. In addition, newer molecules have been developed that are not analogues of prostacyclin but that target the receptors that prostacyclin activates. Prostacyclin and related drugs have without doubt revolutionised the treatment and management of pulmonary arterial hypertension but are seriously limited by side effects within the systemic circulation. With the dawn of nanomedicine and targeted drug or stem cell delivery systems it will, in the very near future, be possible to make new formulations of prostacyclin that can evade the systemic circulation allowing for safe delivery to the pulmonary vessels. In this way, the full therapeutic potential of prostacyclin can be realised opening the possibility that pulmonary arterial hypertension will become, if not curable, a chronic manageable disease that is no longer fatal. This review discusses these and other issues relating to prostacyclin and its use in pulmonary arterial hypertensionen
dc.format.extent12
dc.language.isoeng
dc.relation.ispartofGlobal Cardiology Science and Practice
dc.rightsOpen
dc.titleRole of prostacyclin in pulmonary hypertensionen
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionHealth & Human Sciences Research Institute
dc.contributor.institutionDepartment of Human and Environmental Sciences
dc.contributor.institutionPharmacology and Clinical Science Research
dc.contributor.institutionAgriculture, Veterinary and Food Sciences
dc.contributor.institutionCardiovascular Pathologies
dc.contributor.institutionDiabetic neuropathies
dc.description.statusPeer reviewed
dc.relation.schoolSchool of Life and Medical Sciences
dc.description.versiontypeFinal Published version
dcterms.dateAccepted2014-12-31
rioxxterms.versionVoR
rioxxterms.versionofrecordhttps://doi.org/10.5339/gcsp.2014.53
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue
herts.rights.accesstypeOpen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record